In recent years, a surprising finding in the analysis of human transcriptome is that mRNAs only account for a small portion of the genome transcripts [1] . The majority of the human genome transcripts are noncoding RNAs, especially, long noncoding RNAs (lncRNAs) [2] . Historically, people often argue against the functionality of lncRNAs [3] because they normally tend to show low cross-species conservation, low expression levels and high tissue specificity. Recently, however, increasing evidence has suggested that a number of lncRNAs have important and diverse functions [4] . Therefore, it will be no surprise the dysfunction of lncRNAs is associated with a wide spectrum of disease, including cardiovascular disease [5] and cancer [6] . According to the statistics of the long noncoding RNA disease database (LncRNADisease, http://www.cuilab.cn/lncrnadisease) [7] , more than 200 diseases were reported to be associated with lncRNAs and more than 250 lncRNAs were reported to have roles in disease. Therefore, it is believed that lncRNAs are becoming a large class of novel molecules for disease diagnosis and therapy [8] . Vascular disease represents one class of serious disease that causes lethal death in the world [9] . Given the large number of lncRNAs, however, the relationship between the majority of lncRNAs and human disease including vascular disease remains unknown. Therefore, it is increasingly emergent and important to identify the roles of lncRNAs in vascular disease by developing bioinformatics methods.
For the bioinformatics methods to predict novel lncRNAdisease associations, we previously presented a genomic location based bioinformatics method [7] . Moreover, two bioinformatics methods based on co-expression of lncRNA and protein-coding genes were presented for cancer [10] and human disease [11] , respectively. In addition, a method of Laplacian Regularized Least Squares for lncRNA-disease association (LRLSLDA) based on data from the LncRNADisease database and lncRNA expression profile was developed [12] . More recently, a network based analysis of lncRNA-disease association data in the LncRNADisease database revealed a number of regular patterns between lncRNAs and disease [13] , suggesting that it is feasible to predict novel lncRNA-disease associations. Indeed, in the same study, the authors developed a network-based method to predict novel lncRNA-disease associations [13] . These studies and the presented bioinformatics methods together provide great helps in understanding the roles of lncRNAs in human disease and in finding novel lncRNA-disease associations. Of course, limitations exist in the above studies. For example, the genomic location based method used a genomic distance of 2 kb as the cutoff to finding the neighbor genes of an lncRNA. Moreover, the original method only focused on disease-associated genes but neglected disease-associated gene ontology (GO) and gene mutation (e.g., SNPs). Comprehensive analysis of lncRNA SNPs has showed that SNPs in lncRNAs could contribute to disease susceptibility [14] . For the co-expression based methods, only a small number of lncRNAs have matched tissues with protein-coding genes and lncRNAs does not always have similar function with their co-expressed protein-coding genes. In addition, the lncRNA-disease network methods only focus on a limited number of lncRNAs (~260) contained in the LncRNADisease database and cannot be applied to the majority of human lncRNAs. Therefore, more methods are emergently needed. Here, we focus on vascular disease and improved the genomic location based method in two aspects. One is that we extended the genomic distance to 50 kb, which is suggested to define miRNA clusters in the field of miRNAs, another class of noncoding RNAs. It is known that the miRNAs in one cluster often have similar expression, functions [15] , and disease [16] . That is, we obtained vascular function associated genes first and then identified the lncRNAs within the regions of 50 kb from any of the vascular disease genes. In addition, we considered the vascular related GO terms and vascular disease related SNPs. Together, these lncRNAs are considered to be vascular disease associated lncRNAs. Finally, to evaluate the accuracy of the predictions, we randomly select 10 lncRNAs predicted to be associated with VSMC proliferation and migration for further biological experiment validation. As a result, we confirmed that the prediction has a high accuracy.
Materials and methods

The genomic data used in this study
We downloaded the genomic location data of 32108 human lncRNAs from the LNCipedia database [17] (http://www. lncipedia.org/ ). We downloaded the data of gene-disease from the GAD database [18] (http://geneticassociationdb. nih. gov/). We downloaded the GO from NCBI and disease SNPs from the NHGRI GWAS Catalog [19] (http://www. genome.gov/gwastudies/). We downloaded the genomic location data of reference genes from UCSC [20] (http:// genome.ucsc.edu/).
The flowchart to predict vascular disease associated lncRNAs
As shown in Figure 1 , we manually extracted vascular disease associated genes from the GAD dataset and vascular disease associated SNPs from the NHGRI GWAS Catalog dataset. We then used an in-house java program to extract vascular related GO terms using expert knowledge combined with the following keywords, angiogenesis, angiostatin, arterial, artery, blood, circulation, vascular, vasculogenesis, vasoactive, vasoconstriction, vasodilation, vasomotion, vasopressin, VEGF, vein, and vessel. We next identified the lncRNAs that are within 50 kb from genes associated with vascular disease related genes and genes associated vascular related GO terms. We also identified the lncRNAs that host vascular related SNPs. Together we considered these lncRNAs as putative vascular disease associated lncRNAs.
The model of VSMC proliferation and migration
VSMCs are highly differentiated cells, but they can undergo phenotypic switch from contractile to dedifferentiated phenotype such as synthetic, inflammatory and osteo/ chondrocytic phenotype in response to the change of extracellular matrix. VSMCs' phenotypic transition plays a critical role in angiogenesis and restenosis [21] . During this process, various growth factors and cytokines such as platelet-derived growth factor-BB (PDGF-BB), interleukin-1, tumor necrosis factor α (TNF-α) and fibroblast growth factor (FGF) are markedly increased [22] . PDGF-BB and its signaling is a key regulator to mediate VSMC proliferation and migration. Inflammatory cytokine TNF-α is powerful to promote the secretion of multiple chemokines of VSMCs and regulate VSMC proliferation and migration in aortic wall injury site. Transcriptional activation of VSMCs marker genes was markedly suppressed by using PDGF-BB and TNF-α treatment with primary VSMCs [22, 23] .
Recombinant tumor necrosis factors (TNF-α and PDGF-BB) were purchased from Peprotech Ltd. (Rocky Hill, USA). VSMCs were isolated from the thoracic aortic arteries of Sprague-Dawley rats (body weight 150180 g) as described previously [24] and cells at passages 48 were used in all experiments.
Quantitative real-time PCR analysis
To test the accuracy of the presented method, here we selected 10 lncRNAs predicted to be associated with VSMC proliferation and migration for further experiment validation. We used quantitative real-time PCR analysis to evaluate whether the predicted lncRNAs are deregulated in the treated VSMCs. Real-time PCR amplification involved use of an Mx3000 Multiplex Quantitative PCR System (Stratagene Corp, USA) and Eva Green reagent normalized to that of the internal control β-actin. The 10 candidate lncRNAs and their primer sequences of target genes are listed in Table 1. All amplification reactions were carried out over 40 cycles (an initial stage of 7 min at 94°C, then a three-step program of 30 s at 94°C, 30 s at 60°C and 30 s at 72°C) and were performed in duplicate.
Results
Putative vascular disease associated lncRNAs
The predicted total vascular disease associated lncRNAs, their sequence, the associated disease, GO terms, and SNPs are available at the download page of the LncRNADisease database (http://www.cuilab.cn/lncrnadisease). There are 2983 lncRNAs, 107 lncRNAs, and 72 lncRNAs in the GAD-based predictions, the GO-based predictions, and the SNP-based predictions, respectively. As shown in Figure 2 , all of the 107 GAD-based predictions are included in the GO-based predictions, whereas only 12 of the SNP-based predictions are included in the GO-based predictions. There is no overlap between the GAD-based predictions and the SNP-based predictions. 
lnc-TGFBR2 Sence 5′-TAATCATCCTAGAAGCCCTAC-3′ Antisence 5′-GCCGACCTTGGGTGATACAC-3′ Figure 2 A pie chart for the distribution of predicted vascular disease associated lncRNAs based on the three types (GO-based, GAD-based, and SNP-based) of information.
It will be interesting to find whether some known vascular disease associated lncRNAs are successfully predicted by our method. For this purpose, we first curated the known vascular disease associated lncRNAs reported in previous studies [2527]. They are Lnc-Ang362, eNOS-AS, TIE-AS, MALAT1, and ANRIL. We then matched these lncRNAs with the lncRNAs predicted to be associated with vascular disease. As a result, three (15 antisense transcripts close to eNOS, lnc-CDK5-1:1, lnc-CDK5-2:1lnc-CDK5-2:14; three antisense transcripts close to TIE, lnc-ELOVL1-1:1, lnc-ELOVL1-1:2, and lnc-ELOVL1-1:3; 16 transcripts of ANRIL, lnc-MTAP-1:1lnc-MTAP-1:16) of the five lncRNAs were found, suggesting that these lncRNAs were successfully predicted. For the two lncRNAs that were not predicted, Lnc-Ang362 was not included in the lncRNA sequence database (LNCipedia) used in this study. For MALAT1, its neighboring gene, SCYL1, is not a known vascular-related gene based on GAD and GO datasets. Therefore, these two genes were not predicted to be associated with vascular diseases by this method. This result suggests that the presented method has reliable prediction accuracy.
Validation of putative lncRNAs associated VSMCs proliferation and migration
To evaluate the accuracy of the predictions, we randomly selected 10 lncRNAs associated with VSMCs proliferation and migration for further validation by biological experiments. For this purpose, here we built two cell models, VSMCs treated by PDGF-BB and VSMCs treated by TNF-α. We next used qRT-PCR to evaluate whether the candidate lncRNAs are deregulated in the treated cells compared with the untreated ones. As a result, we found that 70% (7/10) of the candidate lncRNAs showed significant deregulation (P<0.05) in the PDGF-BB treated VSMCs (Figure 3) . Moreover, 50% (5/10) of the candidate lncRNAs showed significant deregulation (P<0.05) in the TNF-α treated VSMCs (Figure 4 ). Together 80% of the candidate lncRNAs are significantly deregulated. The results suggest that these putative lncRNAs could be indeed involved in VSMCs proliferation and migration, which further suggests that the presented method has a reliable accuracy. Moreover, by GO-based method, we know that all of the eight lncRNAs are putatively involved in blood vessel remodeling, blood vessel morphogenesis, artery morphogenesis, and blood vessel development.
Discussion
lncRNAs represent one large class of important noncoding molecules, which play critical roles in human diseases. Vascular disease is one class of serious disease that leads to lethal death in the world. Therefore, it is increasingly emergent and important to rapidly identify lncRNAs that are implicated in vascular disease. In this study, we presented a simple genomic location based in-silico method to predict novel associations of lncRNAs and vascular disease. An independent biological experiment confirmed that the presented method has a reliable accuracy. Of course, limitations exist in the current method. For example, not all of the lncRNAs have at least one neighbor gene within 50 kb distance. Moreover, lncRNAs are not always functional- ly related with their neighbor genes. In addition, no statistical tests were used in the current method. Thus, the method seems to be less quantitative. Although limitations exist, we believe that the presented method and the predicted vascular disease associated lncRNAs provide researchers valuable resources for not only better understanding the roles of lncRNAs in vascular disease but also identifying novel potential biomarkers and drug targets for vascular disease diagnosis and therapy. 
